Do you have any queries?

or Call us now at 9982-782-555

back-arrow-image Search Health Packages, Tests & More

NextGen NIPS Advanced

50+ booked in last 3 days


NextGen NIPS Advanced also known as Non-invasive Prenatal Screening or Non-invasive Prenatal Testing (NIPT) Advanced is a procedure used to assess the likelihood that a foetus would be born with specific genetic disorders.

NextGen NIPS Advanced is a method used to screen for all 23 pairs of chromosomes (22 pairs of autosomes and one pair of sex chromosomes). Rare autosomal aneuploidies (RAA) are aneuploidies that include monosomy and trisomy of chromosomes other than Trisomy 13, 18, and 21. They frequently lead to unfavourable pregnancy outcomes. Cell-free DNA (cfDNA) can be screened to find RAAs. Clinically significant abnormalities are seen in between 30% and 75% of pregnancies with high risk for RAAs according to NIPT. High-risk results call for confirmation diagnostic tests that use karyotyping or chromosomal microarrays to verify the RAA findings.

RAA can lead to miscarriage, preterm delivery, neurodevelopmental delay, structural abnormalities, fetal growth restriction, and uniparental disomy.

Associated Tests:

 NextGen Non-Invasive Prenatal Screening Test

  NIPT Plus (Covers Microdeletions)

 Maternal Screen-1st Trimester Dual Marker Test

  Maternal Screen-2nd Trimester Triple Marker Test

  Maternal Screen-2nd Trimester Quadruple Marker Test


Written by : Supriya Kulkarni, Lead-Content & Training 

Read More

NextGen NIPS Advanced Price

Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the NextGen NIPS Advanced with a clear pricing structure.

The NextGen NIPS Advanced Price in Mumbai is ₹ 19,900 .

We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.

Frequently Asked Questions

  • NextGen NIPS Advanced is intended for use in pregnant women between 10-17 weeks of pregnancy and who are at high risk for the chromosomal aneuploidies.
  • NextGen NIPS Advanced is recommended for pregnant women to screen for chromosomal diseases that are brought on by an extra or missing copy of a chromosome (aneuploidy).
  • NextGen NIPS Advanced is used to determine the risk for the foetus being born with certain genetic abnormalities such as:
  • Down syndrome (trisomy 21, caused by an extra chromosome 21)
  • Edwards syndrome (trisomy 18, caused by an extra chromosome 18)
  • Patau syndrome (trisomy 13, caused by an extra chromosome 13)
  • Extra or missing copies of the X chromosome and Y chromosome, the sex chromosomes)
  • Aneuploidies (missing (deleted) or copied (duplicated) sections of a chromosome)
  • NextGen NIPS Advanced is recommended for all types of pregnancies.
  • NextGen NIPS Advanced is offered to all women after at least 10 weeks of pregnancy.
  • NextGen NIPS Advanced is recommended as the first line of screening for all pregnancies, irrespective of the risk.
  • NextGen NIPS Advanced is especially significant if the woman is above 30 years of age.

NextGen NIPS Advanced measures foetal cell-free DNA (cfDNA) in the mother’s bloodstream to be able to identify foetal chromosomal or genetic abnormalities including rare autosomal aneuploidies (RAA).

This test requires a blood sample. A tourniquet (elastic) band is placed tightly on the upper arm. The patient is then asked to make a fist. This helps in the build-up of blood filling the veins. The skin is disinfected before needle insertion and the blood sample is collected in vacutainer.


The test is performed on ION Genestudio S5 Plus NGS platform and involves isolation of cell free fetal DNA from maternal blood, generation of genomic DNA library, high throughput sequencing of extracted cell free fetal DNA and calculation of molecular mass of fetal DNA in chromosomes. Chromosomal aneuploidies can then be detected using bioinformatics analyses (Sage 12plex analytic program version v.1) where the detection rate and sensitivity are over 99%.

A "low risk" result indicates that there is often very little probability that the baby will have trisomy 21, trisomy 18, or trisomy 13 or any other aneuploidies. A "high risk" indicates that the infant is likely to have one of these chromosomal errors and may result due to true fetal abnormality, fetal mosaicism, placental mosaicism, fetal uniparental disomy, or maternal findings. If your NIPT result is "high risk," you should consult a genetic counsellor who can explain your results, offer assistance, go over your options, and set up additional testing as necessary.

To be able to detect foetal chromosome abnormalities, there must be sufficient foetal cfDNA in the mother's bloodstream. The foetal fraction is the percentage of cfDNA in maternal blood that originates from the placenta. The foetal percentage must normally be greater than 4%, which happens during the ninth week of pregnancy. Low foetal fractions may prevent the test from being run or result in a false negative. Low foetal fractions can be caused by foetal abnormalities, sampling mistakes, maternal obesity, and testing too early in the pregnancy.


full medical check up

Ratings & Reviews (0)

No reviews available

Why Metropolis?

Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.

We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.

lab image
170+ Advanced Labs
lab image
Trusted by Leading Doctors & Hospitals
lab images
Over 2000+ Scientific Officers
reports image
Proficiency Testing for Accurate Reports

Our Blog

Take a look at some of the related content from our blog

Latest Blogs & News

View More
View all